VadimS.KoshkinMD

Oncology • San Francisco, CA

Genitourinary Oncology

Associate Professor of Clinical Medicine, University of California San Francisco

Join to view full profile

Dr. Koshkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Koshkin's full profile

Already have an account?

Office
550 16th Street Office 6811
# 3211
San Francisco, CA 94158

Summary

I am a genitourinary oncologist focused on clinical and translational research and clinical trials in genitourinary malignancies including bladder, prostate and kidney cancer. I graduated from medical school at the University of Chicago and completed training in Internal Medicine at the University of Michigan and Hematology/Oncology at Cleveland Clinic.

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2015 - 2018
University of MichiganResidency, Internal Medicine, 2012 - 2015
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2012, MD
University of PennsylvaniaBA, Cognitive Science, Magna Cum Laude, 2003 - 2007

Certifications & Licensure

CA State Medical License 2018 - 2025
OH State Medical License 2015 - 2018
MI State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Prostate Cancer Foundation Young Investigator Award Prostate Cancer Foundation, 2020
NIH LRP NIH, 2020
John Quale Travel Fellowship Award, BCAN Bladder Cancer Think Tank Bladder Cancer Advocacy Network, 2017
Young Investigator Abstract Award, International Kidney Cancer Symposium Kidney Cancer Association, 2017
Conquer Cancer Foundation Merit Award Conquer Cancer Foundation of ASCO, 2015, 2017
AACR/ASCO Methods in Clinical Cancer Research Workshop Participant AACR/ASCO, 2016
Join now to see all

Clinical Trials

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Start of enrollment: 2017 Feb 15
Completed
Phase 2
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Start of enrollment: 2017 Jun 13
Active, not recruiting
Phase 3
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2018 May 29
Completed
Phase 3
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2022 Jul 08
Recruiting
Phase 1, Phase 2
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2021 Jan 21
Active, not recruiting
Phase 2
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Start of enrollment: 2019 Apr 29
Completed
Phase 2
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) Start of enrollment: 2021 Apr 21
Active, not recruiting
Phase 3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Start of enrollment: 2019 Jan 25
Active, not recruiting
Phase 3
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Start of enrollment: 2022 May 03
Recruiting
Phase 2
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) Start of enrollment: 2021 Jul 30
Active, not recruiting
Phase 1, Phase 2
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Start of enrollment: 2023 Sep 22
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Start of enrollment: 2018 Aug 13
Recruiting
Phase 2
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) Start of enrollment: 2023 Jun 23
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Expanding the Reach of FGFR Inhibitors to Advance Precision Medicine in Urothelial Carcinoma.
Vadim S Koshkin, Guru P Sonpavde
European Urology. 2025-02-01
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, Leonidas N Diamantopoulos, Thomas Enright
Clinical Genitourinary Cancer. 2025-02-01
1 citations
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Vadim S Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, Andrey Semenov, Ozgur Ozyilkan
European Urology. 2024-12-20

Journal Articles

Treatment Selection for Men with Metastatic Prostate Cancer Who Progress on Upfront Chemo‐Hormonal Therapy
Vadim Koshkin, Prateek Mendiratta, Brian I Rini, Pedro Barata, Christos Kyriakopoulos, Hamid Emamekhoo, Timothy Gilligan, The Prostate

Lectures

Ongoing Clinical Trials in Advanced Urothelial Carcinoma and Future Directions
EUSTM-2021: Bladder Cancer Symposium - 6/23/2021
Immunotherapy for Bladder Cancer
Urology COVID Lecture Series - 2/22/2021
Systemic Therapy for Metastatic Urothelial Cancer
Society for Urologic Oncology Annual Meeting - 12/5/2020
Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Authored Content

Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer4/20/2018

Press Mentions

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines StandardsNovember 22nd, 2024
A Novel Imaging Modality, FAP Imaging for Sufferers with Bladder Most CancersOctober 18th, 2022
The Prostate Cancer Foundation Announces 2020 Young Investigator Awards Totaling $6 Million for Prostate Cancer ResearchDecember 16th, 2020
Join now to see all